Targeting estrogen receptor-β for the prevention of nonmelanoma skin cancer

Related Experiment Video

Updated: May 3, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

11.7K

Pei-Li Yao1, Frank J Gonzalez, Jeffrey M Peters

  • 1Department of Veterinary and Biomedical Sciences and Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, Life Sciences Building, University Park, PA 16802. jmp21@psu.edu.

Cancer Prevention Research (Philadelphia, Pa.)
|January 28, 2014
PubMed

Insights

A novel estrogen receptor beta (ER-β) agonist, ERB-041, significantly reduced skin cancer in mice exposed to ultraviolet B (UVB) radiation. This protective effect is linked to reduced inflammation and epithelial-mesenchymal transition (EMT) via WNT/β-catenin signaling.

Area of Science:

  • Oncology
  • Dermatology
  • Endocrinology

Background:

  • Estrogen receptor beta (ER-β) is implicated in various cancer models.
  • Targeting ER-β is a promising strategy for cancer therapy.
  • Ultraviolet B (UVB) radiation is a major cause of skin cancer.

Purpose of the Study:

  • To investigate the efficacy of a specific ER-β agonist, ERB-041, in preventing UVB-induced skin cancer.
  • To elucidate the underlying mechanisms of ERB-041's inhibitory effects.

Main Methods:

  • Utilized a mouse model of UVB-induced skin cancer.
  • Administered the specific ER-β agonist ERB-041.
  • Analyzed molecular pathways including proinflammatory signaling, epithelial-mesenchymal transition (EMT), and WNT/β-catenin signaling.

Main Results:

  • ERB-041 markedly decreased UVB-induced skin cancer development.
  • The protective effect was associated with the inhibition of proinflammatory signaling.
  • ERB-041 modulated epithelial-mesenchymal transition (EMT) and WNT/β-catenin signaling.

Conclusions:

  • ERB-041 demonstrates significant potential as a chemopreventive agent against UVB-induced skin cancer.
  • Inhibition of inflammation and EMT are key mechanisms of ERB-041's action.
  • Further research into combinatorial approaches for skin cancer chemoprevention is warranted.

More Related Videos

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells16:24

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells

Published on: February 21, 2014

23.1K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81